Practical · US & Canada
If you miss a dose
By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due May 1, 2027
Clinical review: not yet reviewed by a clinician. How review works · Editorial policy
Each GLP-1 medicine's label says what to do if a dose is missed, and the rules differ by product. Here is what each current label says, linked to the label itself. Your pharmacist can confirm what applies to your prescription.
What each US label says
| Item | Still OK to take if… | Otherwise |
|---|---|---|
| Ozempic (weekly) | within 5 days of the missed day | skip; resume on your regular day |
| Wegovy injection (weekly) | your next dose is more than 2 days away | skip; take the next dose as scheduled |
| Zepbound (weekly) | within 4 days (96 hours) | skip; resume on your regular day |
| Mounjaro (weekly) | within 4 days (96 hours) | skip; resume on your regular day |
| Wegovy tablets (daily) | — | skip; take the next tablet the following day |
| Rybelsus (daily) | — | skip; take the next tablet the following day |
More than one missed dose
The current Wegovy label says that if two or more weekly doses in a row are missed, dose escalation should be restarted at a lower dose, to reduce stomach side effects[5]. Ask your prescriber before restarting after a gap — don't guess at a dose.
Changing your dose day
The Ozempic label allows changing the weekly day as long as there are at least 2 days (more than 48 hours) between doses[1]. For Zepbound and Mounjaro, doses must be at least 3 days (72 hours) apart[2][3].
In Canada
The Canadian Ozempic monograph has the same 5-day rule[6], and the Canadian Zepbound KwikPen monograph the same 4-day (96-hour) rule[7]. For other products, check your Canadian product monograph or ask your pharmacist.
General information from product labels, not medical advice.
Log each dose and see when the next one is due, on your device. Open my tracker or browse the other guides.
Sources
- OZEMPIC (semaglutide) injection — prescribing information (revised 05/2026). U.S. Food and Drug Administration, May 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf. Accessed November 2, 2026. Back to the text
- ZEPBOUND (tirzepatide) injection — prescribing information, Medication Guide and Instructions for Use (revised 02/2026). U.S. Food and Drug Administration, February 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf. Accessed November 2, 2026. Back to the text
- MOUNJARO (tirzepatide) injection and KwikPen — current label (revised 8/2026). DailyMed (U.S. National Library of Medicine), August 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0. Accessed November 2, 2026. Back to the text
- RYBELSUS (semaglutide) tablets — prescribing information (revised 10/2025). U.S. Food and Drug Administration, October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf. Accessed November 2, 2026. Back to the text
- WEGOVY (semaglutide) injection and tablets — current label (revised 6/2026). DailyMed (U.S. National Library of Medicine), June 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b. Accessed November 2, 2026. Back to the text
- Ozempic (semaglutide injection) product monograph. Health Canada Drug Product Database / Novo Nordisk Canada, April 14, 2026. https://pdf.hres.ca/dpd_pm/00084255.PDF. Accessed November 2, 2026. Back to the text
- Zepbound (tirzepatide injection) KwikPen product monograph. Health Canada Drug Product Database / Eli Lilly Canada, April 2, 2026. https://pdf.hres.ca/dpd_pm/00084150.PDF. Accessed November 2, 2026. Back to the text
Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.
Changes to this page
- — First published.
Substantive corrections are also logged at corrections.